Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists. 2012

Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Dipartimento di Scienze Farmaceutiche, Università di Ferrara, 44100 Ferrara, Italy. baraldi@dns.unife.it

The discovery and development of adenosine receptor antagonists have represented for years an attractive field of research from the perspective of identifying new drugs for the treatment of widespread disorders such as inflammation, asthma and Parkinson's disease. The present work can be considered as an extension of our structure-activity relationship studies on the pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine (PTP) nucleus, extensively investigated by us as a useful template, in particular, for the identification of A(2A) and A(3) adenosine receptor antagonists. In order to explore the role of the nitrogen at the 7-position, we performed a new synthetic strategy for the preparation of pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives which can be considered as 7-deaza analogues of the parent PTPs. We also synthesised a novel series of pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as junction isomers of the reference compounds. In both cases we obtained some examples of potent antagonists (K(i) in the low nanomolar range) with variable selectivity profiles in relation to the nature of substituents introduced at the C(5)-, N(8)- and/or N(9)-positions. The pyrrolo-triazolo-pyrimidine derivative 9b appeared to be a potent A(3) adenosine receptor antagonist (K(i)=10 nM) with good selectivity over hA(1) (74-fold) and hA(2A) (20-fold) adenosine receptors combined with low activity at the hA(2B) subtype (IC(50)=906 nM). Moreover, some examples of high-affinity A(1)/A(2A) dual antagonists have been identified in both series. This work constitutes a new and important contribution for the comprehension of the interaction between PTPs and adenosine receptors.

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D043684 Receptor, Adenosine A3 A subtype of ADENOSINE RECEPTOR that is found expressed in a variety of locations including the BRAIN and endocrine tissues. The receptor is generally considered to be coupled to the GI, INHIBITORY G-PROTEIN which causes down regulation of CYCLIC AMP. Adenosine A3 Receptors,Adenosine A3 Receptor,A3 Receptor, Adenosine,A3 Receptors, Adenosine,Receptors, Adenosine A3
D043705 Receptor, Adenosine A2A A subclass of adenosine A2 receptors found in LEUKOCYTES, the SPLEEN, the THYMUS and a variety of other tissues. It is generally considered to be a receptor for ADENOSINE that couples to the GS, STIMULATORY G-PROTEIN. Adenosine A2A Receptor,Adenosine A(2A) Receptor,Adenosine A2A Receptors,A2A Receptor, Adenosine,A2A Receptors, Adenosine,Receptors, Adenosine A2A
D058915 Purinergic P1 Receptor Antagonists Compounds that bind to and block the stimulation of PURINERGIC P1 RECEPTORS. Adenosine Receptor Antagonist,P1 Purinoceptor Antagonist,Purinergic P1 Receptor Antagonist,Adenosine Receptor Antagonists,P1 Purinoceptor Antagonists,Antagonist, Adenosine Receptor,Antagonist, P1 Purinoceptor,Antagonists, Adenosine Receptor,Antagonists, P1 Purinoceptor,Purinoceptor Antagonist, P1,Purinoceptor Antagonists, P1,Receptor Antagonist, Adenosine,Receptor Antagonists, Adenosine

Related Publications

Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
January 2016, Current topics in medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
February 2009, Bioorganic & medicinal chemistry letters,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
March 2007, Bioorganic & medicinal chemistry letters,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
November 1999, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
March 1996, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
June 1998, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
May 1984, Life sciences,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
March 2003, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
July 2019, MedChemComm,
Pier Giovanni Baraldi, and Giulia Saponaro, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Romeo Romagnoli, and Allan R Moorman, and Katia Varani, and Pier Andrea Borea, and Delia Preti
September 2018, European journal of medicinal chemistry,
Copied contents to your clipboard!